Myelofibrosis / Polycythaemia Vera
A prespecified exploratory biomarker analysis aimed to evaluate potential prognostic or predictive factors and mechanisms of resistance to adjuvant targeted therapy
COMBI-AD is a randomised, double-blind, placebo-controlled, phase 3 trial comparing dabrafenib 150mg orally twice daily plus trametinib 2mg orally once daily versus two matched placebos. Study participants were at least 18 years of age and underwent...
Twitter Linkedin Facebook Pinterest Google plusUseful links
Congress Link to Website AAN, American Academy of Neurology https://www.aan.com/conferences-community/annual-meeting ACTRIMS, American Committee...Twitter Linkedin Facebook Pinterest Google plusUrticaire – Journal quotidien des gonflements sous-cutanés - FR
DownloadUrticaria – Dagboek van onderhuidse zwellingen - NL
DownloadXolair® remboursement prolongation
DownloadXolair® remboursement initiale
DownloadXolair® terugbetaling: verlenging
DownloadXolair® terugbetaling: initiële aanvraag
Download
×